Allogene Therapeutics/$ALLO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Allogene Therapeutics
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Ticker
$ALLO
Sector
Primary listing
Employees
151
Headquarters
Website
ALLO Metrics
BasicAdvanced
$735m
-
-$0.77
0.46
-
Price and volume
Market cap
$735m
Beta
0.46
52-week high
$4.46
52-week low
$0.98
Average daily volume
8.4m
Financial strength
Current ratio
9.647
Quick ratio
9.467
Long term debt to equity
26.045
Total debt to equity
29.064
Interest coverage (TTM)
-153.33%
Profitability
EBITDA (TTM)
-175.705
Management effectiveness
Return on assets (TTM)
-25.97%
Return on equity (TTM)
-52.32%
Valuation
Price to book
1.87
Price to tangible book (TTM)
1.87
Price to free cash flow (TTM)
-4.412
Free cash flow yield (TTM)
-22.67%
Free cash flow per share (TTM)
-0.483
Growth
Earnings per share change (TTM)
-37.35%
3-year earnings per share growth (CAGR)
-32.63%
What the Analysts think about ALLO
Analyst ratings (Buy, Hold, Sell) for Allogene Therapeutics stock.
ALLO Financial Performance
Revenues and expenses
ALLO Earnings Performance
Company profitability
ALLO News
AllArticlesVideos
Allogene Therapeutics Q1 Earnings Call Highlights
MarketBeat·1 month ago
Allogene Therapeutics ends China cell therapy deal with Overland
Reuters·1 month ago
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs